American Transplant Congress
Verici Dx will attend the American Transplant Congress ("ATC") in Philadelphia hosted by the American Society of Transplantation and the American Society of Transplant Surgeons from 1-5 June 2024. We look forward to sharing our work on "Performance of Next-Gen Sequencing Biomarker Tutivia in the Setting of Kidney Delayed Graft Function" on Saturday 1 June 2024, as well as meeting with others to discuss ideas and opportunities at ATC_Booth-215.
ATC provides a forum for the exchange of new scientific data and clinical information relevant to solid organ and tissue transplantation. The event brings together transplant physicians, scientists, nurses, organ procurement personnel, pharmacists, allied health professionals and other transplant professionals.
Commenting on the conference, Dr. Joshua Lee, VP Medical Affairs said:
"DGF is a condition that can lead to a higher risk of rejection. Identifying which patients are likely to experience rejection in this population is an unmet need in transplantation. Verici Dx is excited to present findings in this population from our clinical trial at this prestigious conference.
ATC in Philadelphia is such a great venue to bring together the global transplant community. We are looking forward to discussions in the halls and seeing friends in the community, as well as learning about new developing approaches to treatments and diagnostics that can make the lives of transplant patients better."
AST Cutting Edge of Transplantation conference
We at Verici Dx are excited to be attending the AST Cutting Edge of Transplantation conference from Thursday, February 22nd to Saturday, February 24th.
The overarching goal of the CEoT 2024 is to identify innovative technologies currently utilized to advance the medical field in general and describe how those could intersect with the practice of transplantation. Please do stop by our booth to learn what Tutivia™ is bringing to kidney transplant.
Clarava™ poster presented at ASN Kidney Week 2023
Verici Dx attended and exhibited at the American Society of Nephrology’s annual conference, ASN Kidney Week, from 2-5 November 2023 in Philadelphia, PA. We were delighted to present a poster on the successful international clinical validation study for Clarava™, our pre-transplant blood-based prognostic test for the risk of early acute kidney transplant rejection.
The poster, titled “Multi-Center International Study to Validate a Pre-Transplant Blood-Based Next-Generation Sequencing (NGS) Signature Predicting Risk of Acute Rejection After Kidney Transplant”, described the design and positive results of Clarava's™ successful validation study.
Clarava™ is the only pre-transplant test of its kind currently available that can risk stratify patients based on their likely immune response to a transplanted organ. This allows clinicians to identify patients most likely to require increased monitoring, including increasing or decreasing adjustments in the type, dose, and duration of immunosuppressive agents. Existing approaches to assess rejection risk are standardised and typically based on the recipient's race, age, previous transplant history and whether they have antibodies against common donor antigens. As previously reported, the Clarava™ personalised risk assessment is especially important for the expanding Deceased Donor transplant population.
Sara Barrington, CEO of Verici Dx, said: “ASN Kidney Week is an important platform for Verici Dx to raise awareness of its products including Clarava™, being the largest international gathering attended by kidney health professionals and featuring the latest advances in treatment, research and cutting edge technology in the field of nephrology.”
Verici Dx attended and exhibited at ASN 2022 kidney week national conference
Verici Dx attended and exhibited at the ASN kidney week annual conference, from November 3rd to November 6th, 2022, at the Orlando Convention Center, in Orlando FL.
Verici Dx, Renalytix, AST, and ASN, have partnered to create the Dr. Barbara T. Murphy endowed lectureship starting at ASN Kidney Week 2022. This lectureship commemorates Dr. Murphy and her legacy in transplant immunology, by recognizing advances in kidney transplantation. We were honored to have the first lecture be presented by Rosyln B Mannon, Md, FASN, entitled; Improving kidney graft Long-Term Outcomes: Lessons Learned and New Perspectives.
Dr. Oriol Bestard did an oral presentation; “Clinical performance validation of Tutivia™ Biomarker” at the ASN kidney week national conference, during the session titled: Transplantation: Clinical Outcomes and Biomarkers.